Securities code: Realcan Pharmaceutical Group Co.Ltd(002589) securities abbreviation: Realcan Pharmaceutical Group Co.Ltd(002589) Announcement No.: 2022021 Realcan Pharmaceutical Group Co.Ltd(002589)
Announcement of abnormal fluctuations in stock trading
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Introduction to abnormal fluctuations in stock trading
Realcan Pharmaceutical Group Co.Ltd(002589) (stock abbreviation: Realcan Pharmaceutical Group Co.Ltd(002589) , stock code: Realcan Pharmaceutical Group Co.Ltd(002589) , hereinafter referred to as “the company”) the stock trading price deviated from the closing price by more than 20% in two consecutive trading days on March 31, 2022 and April 1, 2022. According to the relevant provisions of the trading rules of Shenzhen Stock Exchange, it is an abnormal fluctuation of stock trading.
2、 Description of the company’s concern and verification
In view of the abnormal fluctuation of the company’s stock trading, the company conducted a self-examination and verified the relevant matters with the controlling shareholders, actual controllers, shareholders holding more than 5%, all directors, supervisors and senior managers of the company. The relevant information is explained as follows:
1. There is no need to correct or supplement the information disclosed by the company in the early stage;
2. The company has not found any unpublished material information that may or has had a great impact on the stock trading price of the company reported by the public media recently;
3. Recently, the company’s production and operation are normal, and the internal and external business environment has not changed significantly;
4. After asking the controlling shareholders, actual controllers, shareholders holding more than 5% of the shares, all directors, supervisors and senior managers of the company, there are no major matters that should be disclosed but not disclosed about the company, and there are no major matters in the planning stage;
5. Upon inquiry, the controlling shareholders, actual controllers and shareholders holding more than 5% of the company’s shares, and all directors, supervisors and senior managers did not buy or sell the company’s shares during the abnormal fluctuation of the company’s stock trading.
3、 Whether there is a description of the information that should be disclosed but not disclosed
The board of directors of the company confirms that the company has no undisclosed matters or planning, negotiation, intention, agreement, etc. related to the matters that should be disclosed in accordance with the relevant provisions of the Listing Rules of Shenzhen Stock Exchange; The board of directors has not been informed that the company has undisclosed information that has a great impact on the trading price of the company’s shares that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant provisions; The information disclosed by the company in the early stage does not need to be corrected or supplemented.
4、 Necessary risk tips
1. The company has not violated the fair disclosure of information through self-examination;
2. The company does not need to disclose the performance forecast, and has not provided the company’s undisclosed performance information to a third party other than the company’s annual report audit accounting firm.
3. The company solemnly reminds investors: securities times, China Securities News, Shanghai Securities News, securities daily and cninfo（ http://www.cn.info.com.cn. ）As the information disclosure media designated by the company, all information of the company shall be subject to the information published in the above designated media. The company will conscientiously perform the obligation of information disclosure and do a good job of information disclosure in a timely manner in strict accordance with the provisions and requirements of relevant laws and regulations.
Please invest rationally and pay attention to risks.
It is hereby announced.
Realcan Pharmaceutical Group Co.Ltd(002589) board of directors
April 2, 2022
